Windtree Therapeutics, Inc. (WINTW)
USD 0.0
(-61.11%)
USD 0.0
(-61.11%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -82 Thousand USD | 92.27% |
| 2022 | -1.06 Million USD | -22.09% |
| 2021 | -869 Thousand USD | -36.21% |
| 2020 | -638 Thousand USD | -422.22% |
| 2019 | 198 Thousand USD | -88.93% |
| 2018 | 1.78 Million USD | 20.4% |
| 2017 | 1.48 Million USD | -16.9% |
| 2016 | 1.78 Million USD | 2981.03% |
| 2015 | 58 Thousand USD | -64.63% |
| 2014 | 164 Thousand USD | 227.13% |
| 2013 | -129 Thousand USD | -166.15% |
| 2012 | 195 Thousand USD | -66.49% |
| 2011 | 582 Thousand USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | -100.0% |
| 2008 | 4.6 Million USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | -100.0% |
| 2005 | 134 Thousand USD | -88.92% |
| 2004 | 1.2 Million USD | 16.59% |
| 2003 | 1.03 Million USD | -41.81% |
| 2002 | 1.78 Million USD | 60.25% |
| 2001 | 1.11 Million USD | 28.7% |
| 2000 | 864 Thousand USD | 226.04% |
| 1999 | 265 Thousand USD | 32.5% |
| 1998 | 200 Thousand USD | -71.43% |
| 1997 | 700 Thousand USD | 177.78% |
| 1996 | -900 Thousand USD | -280.0% |
| 1995 | 500 Thousand USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -24 Thousand USD | -14.29% |
| 2024 Q1 | -21 Thousand USD | 4.55% |
| 2023 Q2 | -120 Thousand USD | 13.67% |
| 2023 Q4 | -22 Thousand USD | -57.14% |
| 2023 FY | -82 Thousand USD | 92.27% |
| 2023 Q3 | -14 Thousand USD | 88.33% |
| 2023 Q1 | -139 Thousand USD | -2.96% |
| 2022 FY | -1.06 Million USD | -22.09% |
| 2022 Q1 | -640 Thousand USD | -185.71% |
| 2022 Q2 | -155 Thousand USD | 75.78% |
| 2022 Q3 | -131 Thousand USD | 15.48% |
| 2022 Q4 | -135 Thousand USD | -3.05% |
| 2021 Q3 | -216 Thousand USD | -0.93% |
| 2021 Q2 | -214 Thousand USD | 0.47% |
| 2021 Q1 | -215 Thousand USD | 0.0% |
| 2021 FY | -869 Thousand USD | -36.21% |
| 2021 Q4 | -224 Thousand USD | -3.7% |
| 2020 Q4 | - USD | 0.0% |
| 2020 Q1 | - USD | 0.0% |
| 2020 Q2 | - USD | 0.0% |
| 2020 FY | -638 Thousand USD | -422.22% |
| 2020 Q3 | - USD | 0.0% |
| 2019 FY | 198 Thousand USD | -88.93% |
| 2019 Q4 | - USD | 0.0% |
| 2019 Q3 | - USD | -100.0% |
| 2019 Q2 | 158 Thousand USD | 295.0% |
| 2019 Q1 | 40 Thousand USD | -86.84% |
| 2018 Q3 | 229 Thousand USD | -78.21% |
| 2018 FY | 1.78 Million USD | 20.4% |
| 2018 Q1 | 204 Thousand USD | 100.0% |
| 2018 Q2 | 1.05 Million USD | 415.2% |
| 2018 Q4 | 304 Thousand USD | 32.75% |
| 2017 Q1 | 219 Thousand USD | -75.67% |
| 2017 Q2 | 1.14 Million USD | 423.74% |
| 2017 Q4 | 102 Thousand USD | 500.0% |
| 2017 Q3 | 17 Thousand USD | -98.52% |
| 2017 FY | 1.48 Million USD | -16.9% |
| 2016 FY | 1.78 Million USD | 2981.03% |
| 2016 Q4 | 900 Thousand USD | -6.35% |
| 2016 Q1 | 75 Thousand USD | -88.55% |
| 2016 Q3 | 961 Thousand USD | 806.6% |
| 2016 Q2 | 106 Thousand USD | 41.33% |
| 2015 Q1 | -738 Thousand USD | -361.7% |
| 2015 Q3 | 66 Thousand USD | -12.0% |
| 2015 Q2 | 75 Thousand USD | 110.16% |
| 2015 Q4 | 655 Thousand USD | 892.42% |
| 2015 FY | 58 Thousand USD | -64.63% |
| 2014 Q4 | 282 Thousand USD | 4.44% |
| 2014 Q1 | -750 Thousand USD | -69.3% |
| 2014 Q3 | 270 Thousand USD | -25.41% |
| 2014 Q2 | 362 Thousand USD | 148.27% |
| 2014 FY | 164 Thousand USD | 227.13% |
| 2013 Q2 | 182 Thousand USD | 152.78% |
| 2013 Q4 | -443 Thousand USD | -838.33% |
| 2013 Q3 | 60 Thousand USD | -67.03% |
| 2013 Q1 | 72 Thousand USD | -63.08% |
| 2013 FY | -129 Thousand USD | -166.15% |
| 2012 Q3 | - USD | 0.0% |
| 2012 Q4 | 195 Thousand USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2012 FY | 195 Thousand USD | -66.49% |
| 2012 Q1 | - USD | 0.0% |
| 2011 Q2 | 201 Thousand USD | -47.24% |
| 2011 Q4 | - USD | 0.0% |
| 2011 FY | 582 Thousand USD | 0.0% |
| 2011 Q3 | - USD | -100.0% |
| 2011 Q1 | 381 Thousand USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| 2010 Q1 | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 FY | - USD | -100.0% |
| 2009 Q2 | - USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2008 FY | 4.6 Million USD | 0.0% |
| 2008 Q3 | 50 Thousand USD | -98.0% |
| 2008 Q4 | - USD | -100.0% |
| 2008 Q2 | 2.5 Million USD | 21.95% |
| 2008 Q1 | 2.05 Million USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2007 Q1 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2006 FY | - USD | -100.0% |
| 2006 Q4 | - USD | 0.0% |
| 2006 Q1 | - USD | -100.0% |
| 2006 Q2 | - USD | 0.0% |
| 2005 FY | 134 Thousand USD | -88.92% |
| 2005 Q2 | 24 Thousand USD | -60.66% |
| 2005 Q1 | 61 Thousand USD | -54.48% |
| 2005 Q3 | 20 Thousand USD | -16.67% |
| 2005 Q4 | 29 Thousand USD | 45.0% |
| 2004 Q2 | 697 Thousand USD | 390.85% |
| 2004 Q4 | 134 Thousand USD | -43.22% |
| 2004 Q3 | 236 Thousand USD | -66.14% |
| 2004 FY | 1.2 Million USD | 16.59% |
| 2004 Q1 | 142 Thousand USD | -21.98% |
| 2003 FY | 1.03 Million USD | -41.81% |
| 2003 Q3 | 198 Thousand USD | -24.71% |
| 2003 Q2 | 263 Thousand USD | -33.08% |
| 2003 Q1 | 393 Thousand USD | -0.25% |
| 2003 Q4 | 182 Thousand USD | -8.08% |
| 2002 Q2 | 783 Thousand USD | 230.38% |
| 2002 Q1 | 237 Thousand USD | 151.41% |
| 2002 Q3 | 368 Thousand USD | -53.0% |
| 2002 Q4 | 394 Thousand USD | 7.07% |
| 2002 FY | 1.78 Million USD | 60.25% |
| 2001 Q1 | 805 Thousand USD | 269.27% |
| 2001 Q4 | -461 Thousand USD | -334.01% |
| 2001 FY | 1.11 Million USD | 28.7% |
| 2001 Q3 | 197 Thousand USD | -70.99% |
| 2001 Q2 | 679 Thousand USD | -15.65% |
| 2000 Q4 | 218 Thousand USD | -62.02% |
| 2000 Q3 | 574 Thousand USD | 1813.33% |
| 2000 Q2 | 30 Thousand USD | -53.85% |
| 2000 Q1 | 65 Thousand USD | 285.71% |
| 2000 FY | 864 Thousand USD | 226.04% |
| 1999 Q1 | 100 Thousand USD | 133.33% |
| 1999 Q4 | -35 Thousand USD | -117.5% |
| 1999 Q3 | 200 Thousand USD | 100.0% |
| 1999 FY | 265 Thousand USD | 32.5% |
| 1999 Q2 | 100 Thousand USD | 0.0% |
| 1998 Q4 | -300 Thousand USD | -400.0% |
| 1998 Q3 | 100 Thousand USD | 0.0% |
| 1998 Q2 | 100 Thousand USD | 0.0% |
| 1998 Q1 | 100 Thousand USD | -83.33% |
| 1998 FY | 200 Thousand USD | -71.43% |
| 1997 Q2 | 100 Thousand USD | 133.33% |
| 1997 Q1 | -300 Thousand USD | 72.73% |
| 1997 Q3 | 200 Thousand USD | 100.0% |
| 1997 FY | 700 Thousand USD | 177.78% |
| 1997 Q4 | 600 Thousand USD | 200.0% |
| 1996 Q4 | -1.1 Million USD | -1200.0% |
| 1996 Q3 | 100 Thousand USD | 0.0% |
| 1996 Q2 | 100 Thousand USD | 0.0% |
| 1996 FY | -900 Thousand USD | -280.0% |
| 1996 Q1 | 100 Thousand USD | 0.0% |
| 1995 Q4 | - USD | -100.0% |
| 1995 Q2 | -400 Thousand USD | -100.0% |
| 1995 FY | 500 Thousand USD | 0.0% |
| 1995 Q3 | 100 Thousand USD | 125.0% |
| 1995 Q1 | -200 Thousand USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Arch Therapeutics, Inc. | -2439.00 USD | -3262.034% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 100.7% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 74.335% |
| Rebus Holdings, Inc. | - USD | Infinity% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 100.069% |
| Qrons Inc. | - USD | Infinity% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 99.682% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | -69.916% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 34.005% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 100.547% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | 2743.456% |
| Institute of Biomedical Research Corp. | - USD | Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | 100.837% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | 224.757% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | -140.117% |
| Mesoblast Limited | -35.16 Million USD | 99.767% |
| Marizyme, Inc. | 457.7 Thousand USD | 117.916% |
| Genus plc | 178.7 Million USD | 100.046% |
| VioQuest Pharmaceuticals, Inc. | - USD | Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 100.037% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | 231.778% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | 119.992% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | -645.455% |
| ContraFect Corporation | -154 Thousand USD | 46.753% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | -64.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | 206.825% |
| IMV Inc. | -962.29 Thousand USD | 91.479% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 78.839% |
| MultiCell Technologies, Inc. | 49.32 USD | 166361.152% |
| ONE Bio Corp. | 20.12 Million USD | 100.407% |
| Accustem Sciences Inc. | - USD | Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 100.204% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | 267.689% |
| Q BioMed Inc. | -8988.00 USD | -812.328% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 100.29% |
| Mosaic ImmunoEngineering Inc. | - USD | Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | -431.639% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 100.185% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 92.817% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | 217.143% |
| GlobeStar Therapeutics Corporation | - USD | Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | -1555.897% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | 158.363% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 15.91% |
| GB Sciences, Inc. | -624.00 USD | -13041.026% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 4.682% |
| HST Global, Inc. | - USD | Infinity% |
| CSL Limited | 7.56 Billion USD | 100.001% |
| Wesana Health Holdings Inc. | - USD | Infinity% |
| Halberd Corporation | -208.00 USD | -39323.077% |
| Enzolytics Inc. | 30.7 Thousand USD | 367.031% |
| Agentix Corp. | - USD | Infinity% |
| Resverlogix Corp. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | 116.997% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | 1.1 Billion USD | 100.007% |
| Enzon Pharmaceuticals, Inc. | - USD | Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 84.063% |
| RespireRx Pharmaceuticals Inc. | - USD | Infinity% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | 113.282% |
| Zenith Capital Corp. | - USD | Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 100.02% |
| Ember Therapeutics, Inc. | - USD | Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | -825.926% |
| WPD Pharmaceuticals Inc. | - USD | Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 2.205% |
| Kadimastem Ltd | -630.13 Thousand USD | 86.987% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | 108.3% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 100.853% |
| BioStem Technologies, Inc. | 15.42 Million USD | 100.532% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | - USD | Infinity% |
| LadRx Corporation | -11.83 Thousand USD | -592.86% |
| Cell Source, Inc. | - USD | Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 146.443% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 146.443% |
| NovAccess Global Inc. | - USD | Infinity% |
| Affymax, Inc. | 1.35 Million USD | 106.042% |
| Itoco Inc. | - USD | Infinity% |
| Rasna Therapeutics, Inc. | - USD | Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | Infinity% |
| Mobile Lads Corp. | - USD | Infinity% |
| CytoDyn Inc. | -29 Thousand USD | -182.759% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | - USD | Infinity% |
| NanoSphere Health Sciences Inc. | - USD | Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | 118.22% |
| SYBLEU INC | 11.69 Thousand USD | 801.094% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 101.78% |
| Bioxytran, Inc. | -8285.00 USD | -889.74% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | - USD | Infinity% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | - USD | Infinity% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | - USD | Infinity% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | - USD | Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 78.016% |
| Neutra Corp. | 14.33 Thousand USD | 672.027% |
| PureTech Health plc | -1.6 Million USD | 94.885% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 91.81% |
| IXICO plc | 3.27 Million USD | 102.508% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 88.184% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 95.422% |
| CSL Limited | 7.7 Billion USD | 100.001% |
| Cellectis S.A. | 18 Thousand USD | 555.556% |